Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could stop hives from scratching or cold

NCT ID NCT06603220

Disease control Sponsor: Evommune, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2a trial tested an oral drug called EVO756 in 30 adults with chronic inducible urticaria, a condition where physical triggers like scratching or cold cause hives. The study aimed to see if the drug is safe and can reduce wheals. Results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
EVO756
What this could lead to
If successful, EVO756 could offer a new treatment option for people with chronic inducible urticaria, reducing hives triggered by physical stimuli like scratching or cold.
What could go wrong
This is a small, early-phase (2a) trial with only 30 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

30 people

The number who actually took part.

Started

Aug 2024

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of chronic inducible urticaria for at least 3 months. * Positive response following provocation using the TempTest or FricTest at Screening and Day 1. Exclusion Criteria: * History of diseases other than chronic inducible urticaria or chronic spontaneous urticaria with urticaria or angioedema symptoms, such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema. * Concurrent use of certain medications, including antihistamines. * Any clinically significant disease, or other skin disease or skin markings (e.g., extensive scarring, tattoos), that might confound the evaluation of safety or efficacy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic inducible urticaria are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic inducible urticaria cold urticaria familial dermatographia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic inducible urticaria

Contacts and locations

Locations

  • Advanced Clinical Research Institute

    Tampa, Florida, 33607, United States

  • Aeroallergy Research Laboratories of Savannah, Inc.

    Savannah, Georgia, 31406, United States

  • Allergy and Clinical Immunology Associates

    Pittsburgh, Pennsylvania, 15241, United States

  • Allergy, Asthma, and Clinical Research Center

    Oklahoma City, Oklahoma, 73120, United States

  • Austin Institute for Clinical Research

    Pflugerville, Texas, 78660, United States

  • Bexley Dermatology Research

    Bexley, Ohio, 43209, United States

  • Cahaba Dermatology & Skin Health Center, LLC

    Birmingham, Alabama, 35244, United States

  • California Allergy and Asthma Medical Group

    Los Angeles, California, 90025, United States

  • Chesapeake Clinical Research, Inc

    White Marsh, Maryland, 21162, United States

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana, 46250, United States

  • DelRicht Research

    Baton Rouge, Louisiana, 70809, United States

  • Indiana Clinical Trials Center, P.C.

    Plainfield, Indiana, 46168, United States

  • Integrative Skin Science and Research

    Sacramento, California, 95815, United States

  • OptiSkin Medical

    New York, New York, 10128, United States

  • Red River Research Partners

    Fargo, North Dakota, 58013, United States

  • Southern Indiana Clinical Trials

    New Albany, Indiana, 47150, United States

  • Treasure Valley Medical Research

    Boise, Idaho, 83706, United States

  • West Dermatology Research Center

    San Diego, California, 92121, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.